Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -45.95% | -72.02% | -72.88% | -70.32% | -42.07% |
| Total Depreciation and Amortization | 8.57% | 2.86% | 11.76% | 84.21% | 133.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 286.14% |
| Total Other Non-Cash Items | 171.76% | 180.79% | 692.98% | 656.63% | 288.13% |
| Change in Net Operating Assets | 37.09% | 1,423.19% | 191.60% | 96.58% | 194.12% |
| Cash from Operations | -50.18% | -31.28% | 12.07% | -27.69% | -0.44% |
| Capital Expenditure | 68.18% | 100.00% | 30.00% | -- | 81.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -285.47% | -57.41% | -85.79% | -189.71% | 126.70% |
| Cash from Investing | -285.85% | -57.36% | -85.91% | -190.28% | 126.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 3.13% | -3.23% | 99.60% | 98.17% | 98.17% |
| Issuance of Common Stock | 142,950.00% | 192.47% | 12,334.15% | -93.55% | -98.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 20.55% |
| Cash from Financing | 95,409.26% | 229.67% | 166.12% | 98.36% | -108.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 180.55% | -74.71% | -140.36% | -1,881.45% | 111.91% |